Generalized Anxiety Disorder

Saturday, May 09, 2026

🔬 Practice-Changing Findings
Evidence from RCTs and meta-analyses published in the last 12 months.

1. CBT treatment delivery formats for generalized anxiety disorder: a systematic review and network meta-analysis of randomized controlled trials.

Translational Psychiatry (2025) - Network Meta-Analysis

Key Findings

Individual CBT reduced anxiety symptoms more than remote CBT (SMD 0.96, 95% CI 0.13-1.79), treatment as usual (SMD 1.12, 95% CI 0.24-2.00), and waiting list (SMD 1.62, 95% CI 1.03-2.22).
Group CBT also outperformed waiting list (SMD 1.65, 95% CI 0.47-2.84), while remote CBT was not superior to treatment as usual or waiting list.
Acceptability showed no meaningful increase or reduction versus other CBT delivery formats.

📋 Practice Implication: When psychotherapy access is limited, prioritize referral to individual CBT first and consider group CBT before assuming remote CBT will deliver comparable symptom relief.

2. (Third-wave) cognitive behavioral therapy for generalized anxiety disorder in adults: A systematic review and Bayesian network meta-analysis.

Journal of Psychiatric Research (2025) - Network Meta-Analysis

Key Findings

Across 56 studies, Dugas's CBT protocol showed superior short- and long-term efficacy in reducing GAD symptom severity versus other CBT protocols in the network.
Acceptance-based therapy also improved GAD symptoms in short- and long-term comparisons among third-wave CBT options.
Clinician-guided treatment improved effect size versus control conditions more than unguided approaches in the meta-regression.

📋 Practice Implication: For persistent GAD, refer toward uncertainty-focused or acceptance-based CBT models and favor clinician-guided delivery when choosing among psychotherapy options.

3. Efficacy of a Smartphone-Based Digital Therapeutic (Anzeilax) in Generalized Anxiety Disorder: Randomized Controlled Trial.

Journal of Medical Internet Research (2025) - Randomized Controlled Trial

Key Findings

At 10 weeks, Anzeilax plus treatment as usual reduced GAD-7 scores more than treatment as usual alone (adjusted mean difference -2.26, 95% CI -3.78 to -0.74; P=.002).
Secondary anxiety outcomes also improved, including BAI (Cohen d=0.50; P=.008), PSWQ (Cohen d=0.62; P=.002), and HADS-A (Cohen d=0.50; P=.01).
Anxiety symptom improvement was sustained at week 15 follow-up versus baseline.

📋 Practice Implication: An ACT-based prescription digital therapeutic can be a practical adjunct when patients need scalable treatment between visits or cannot readily access in-person therapy.

4. An updated systematic review and meta-analysis of the predictive validity of the general anxiety disorder (GAD)-7 and GAD-2 in screening for anxiety disorders.

Journal of Affective Disorders (2025) - Systematic Review

Key Findings

GAD-7 showed sensitivity 0.81 (95% CI 0.78-0.84), specificity 0.78 (95% CI 0.74-0.81), and AUC 0.87 across 43 studies.
GAD-2 showed sensitivity 0.78 (95% CI 0.73-0.83), specificity 0.81 (95% CI 0.73-0.86), and AUC 0.86 across 13 studies.
For GAD specifically, GAD-7 had higher screening accuracy than for other anxiety targets, with AUC 0.88 versus 0.84.

📋 Practice Implication: Keep GAD-7 as the default office screening instrument and use GAD-2 as a brief triage option when workflow or visit time is constrained.

5. Prevalence of sleep disturbances and its associated factors in patients with generalised anxiety disorder: A systematic review and meta-analysis.

Journal of Psychosomatic Research (2025) - Systematic Review

Key Findings

The pooled prevalence of sleep disturbance in GAD was 72% (95% CI 28-99%) across five studies including 5875 patients.
Sleep disturbance increased alongside higher GAD severity, higher depression scores, worse health-related quality of life, and factors including BMI and cigarette use.
The very broad confidence interval indicates substantial heterogeneity, but sleep problems remained consistently common across included studies.

📋 Practice Implication: Routine GAD follow-up should include targeted sleep assessment and management because insomnia-related burden is common and tracks with worse symptom severity and quality of life.

💡 Summary

Recent GAD evidence was dominated by psychotherapy optimization, digital therapeutics, and screening-validation studies rather than new pharmacologic trials. Individual CBT and uncertainty-focused CBT protocols showed the strongest treatment effects, ACT-based digital programs reduced GAD symptom scores in randomized trials, and GAD-7/GAD-2 remained the best-supported brief screening tools. Sleep disturbance remained highly prevalent in GAD, reinforcing the need to address insomnia and related contributors as part of routine management.